Ulka Nitin Vaishampayan, MBBS

Ulka Nitin Vaishampayan, MBBS, discusses the rationale for conducting the phase 3 SWOG 1931 trial in patients with advanced renal cell carcinoma.

Ulka Nitin Vaishampayan, MBBS, discusses the need for improved identification of patients with homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer who may benefit from treatment with talazoparib and enzalutamide.

Ulka Nitin Vaishampayan, MBBS, discusses findings from the phase 3 CONTACT-03 trial in patients with renal cell carcinoma.

Ulka Nitin Vaishampayan, MBBS, discusses updated data for frontline TKI combination therapies in the treatment of patients with metastatic renal cell carcinoma.

Ulka Nitin Vaishampayan, MBBS, discusses the intent of the phase 3 PROBE trial in advanced renal cell carcinoma.